Welcome to our dedicated page for Genmab A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the disclosures of a foreign private issuer in biotechnology, with Form 6-K reports covering interim financial results, company announcements and exhibits incorporated by reference into S-8 registration statements. The filings describe antibody-medicine revenue drivers, collaboration royalties related to DARZALEX and Kesimpta, and pipeline disclosures for programs including EPKINLY, Rina-S and petosemtamab.
The company’s regulatory reports also record Danish capital-markets announcements, major shareholder notifications, share-capital reductions, voting-rights disclosures and governance-related corporate actions. These filings frame Genmab’s public-company record around operating performance, capital structure, ownership reporting, product-regulatory updates and risks tied to developing and commercializing antibody therapeutics.
Genmab A/S will increase its share capital by 2,346 shares after employees exercised warrants, a very small change equal to about 0.004% of the company’s share capital.
The new shares were subscribed for cash at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating approximately DKK 3.0 million in proceeds for Genmab. These are ordinary shares with standard rights, including dividends, from the date of subscription.
After the capital increase, Genmab’s total nominal share capital will be DKK 62,353,067, corresponding to 62,353,067 shares with one vote each. The new shares will be listed on Nasdaq Copenhagen once the increase is registered with the Danish Business Authority.
Genmab A/S reports a change in a major shareholder’s position. Orbis Investment Management Limited informed Genmab that, as of May 8, 2026, it controlled voting rights attached to 3,166,357 Genmab shares, equal to 5.08% of the company’s share capital and voting rights.
A related Danish major holdings notification shows the Allan & Gill Gray Foundation group increasing its voting rights in Genmab to 5.0783%, up from 4.8471%, out of a total of 62,350,721 voting rights in the issuer. The filing also confirms there are no additional holdings via financial instruments.
Genmab A/S has completed a share capital reduction approved at its March 19, 2026 Annual General Meeting. The company cancelled 1,900,000 of its own shares, each with a nominal value of DKK 1, reducing the total nominal share capital by DKK 1,900,000.
After this reduction, Genmab’s total share capital is DKK 62,350,721, represented by 62,350,721 shares of DKK 1 each, corresponding to the same number of votes. The change has been registered with the Danish Business Authority and will be reflected in Nasdaq’s systems, which the company expects on April 21, 2026.
Genmab A/S reports a major shareholder update involving Orbis Investment Management Limited. As of April 13, 2026, Orbis controlled the voting rights to 3,114,318 Genmab shares, equal to 4.85% of the share capital and voting rights. This represents a small decrease from a previously reported level of about 5.01%. The notice is made under Section 30 of the Danish Capital Markets Act and confirms Orbis’ position as a significant, but minority, shareholder in Genmab.
Genmab A/S filed a Form 6-K detailing routine equity compensation events for several senior leaders. On April 1, 2026, restricted stock units vested into Genmab shares for President & CEO Jan van de Winkel, CFO Anthony Pagano and four other executive vice presidents. Each transaction is reported as an acquisition of shares due to vesting of restricted stock units, conducted outside the market at a reference price of DKK 1,758.50 per share. The filing is also incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S reports a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,221,620 Genmab shares, equal to 5.01% of the company’s share capital and voting rights as of March 31, 2026.
The filing reflects a small increase from a prior 4.99% position and confirms that the holding is via shares only, with no additional voting exposure through financial instruments.
Genmab A/S has published a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,205,763 Genmab shares, equal to 4.99% of the company’s share capital and voting rights as of March 27, 2026. This represents a small decrease from a previous reported position of 5.03% of voting rights. The issuer’s total voting rights and share capital are stated as 64,250,721.
Genmab A/S reports changes to its board leadership and new employee equity incentives. Following the Annual General Meeting, Deirdre P. Connelly was appointed Chair of the Board and Pernille Erenbjerg was appointed Deputy Chair.
The company decided to grant 5,213 restricted stock units and 4,485 warrants to employees of Genmab and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the closing share price of DKK 1,645.00 at grant, and vests after three years subject to program conditions. Each warrant is also granted cost-free with an exercise price of DKK 1,645.00, has a fair value of DKK 530.62 based on the Black-Scholes formula, vests after three years, and expires seven years from the grant date.
Genmab A/S held its Annual General Meeting on March 19, 2026, where shareholders approved the 2025 Annual Report and gave discharge to the Board of Directors and Executive Management. The year’s profit of USD 963 million will be carried forward to retained earnings.
Six directors were re-elected for one year, and Deloitte was re-appointed as auditor. Shareholders also approved a reduction of the company’s share capital by nominally DKK 1,900,000 through cancellation of treasury shares. The proposal on 2026 Board remuneration was withdrawn, with a new proposal to be presented later.